Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Net Change in Cash : $-2,865 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Takeda Pharmaceutical Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Takeda Pharmaceutical Co's Net Change in Cash for the three months ended in Dec. 2023 was $-206 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-2,865 Mil.

Takeda Pharmaceutical Co Net Change in Cash Historical Data

The historical data trend for Takeda Pharmaceutical Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Net Change in Cash Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Change in Cash

Get a 7-Day Free Trial

3,668.65

-604.72

3,023.10

-982.71

-2,365.37

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-837.53	-1,134.27	-1,536.16	11.30	-206.23

Takeda Pharmaceutical Co Net Change in Cash Calculation

Takeda Pharmaceutical Co's Net Change in Cash for the fiscal year that ended in Mar. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	7310.523	+	-4541.991	+	-5305.441	+	171.542
	=	-2,365

Takeda Pharmaceutical Co's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 1017.152 + -522.769 + -678.976 + -21.635

= -206

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,865 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (OTCPK:TKPHF) » Definitions » Net Change in Cash

Comparable Companies

TSE:4523 TSE:4507 TSE:4581 TSE:4516 TSE:4530 TSE:4887 TSE:4540 TSE:4506 TSE:4547 TSE:4521 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA XSWX:SDZ VTRS NBIX SZSE:000538 NSE:DIVISLAB HKSE:03692

Traded in Other Exchanges

TAK:USA TAK:Mexico 4502:Japan TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Headlines

From GuruFocus

U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
By Business Wire Business Wire • 05-17-2023

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
By Business Wire Business Wire • 06-15-2023

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
By Business Wire Business Wire • 03-30-2023

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
By Business Wire Business Wire • 05-11-2023

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
By Business Wire • 10-18-2023

Takeda Receives U.S. FDA Approval of FRUZAQLA� (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
By Business Wire • 11-08-2023

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
By Business Wire Business Wire • 03-30-2023

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA� as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
By Business Wire Business Wire • 06-20-2023

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
By Business Wire • 12-05-2023

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
By Business Wire Business Wire • 05-25-2023